Thiamine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Thiamine
- Pharmacist Assessment Report
- Thiamine: Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Thiamine: Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta
One-Sentence Summary
Thiamine (vitamin B1) is marketed in Canada, but the data compiled for this report contain no approved indication text, so its original use cannot be stated from the records. The TxGNN model gives its highest prediction score to resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta, with 0 clinical trials and 0 publications supporting this direction. Evidence is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta |
| TxGNN Prediction Score | 0.9943 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 7 of 9; dormant: 2) |
| Number of DINs | 9 (marketed: 7) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Thiamine is known as a cofactor for carbohydrate-metabolism enzymes such as pyruvate dehydrogenase and transketolase, but this report cannot confirm the original indication from the licence records.
No mechanistic link to thyroid hormone receptor beta signalling is supported by the data compiled for this report. The condition is caused by a receptor mutation, and nothing indicates that thiamine’s metabolic role affects that defect. The high score (0.9943) is a model output only and should be treated as a hypothesis, not as evidence of benefit.
For context, the same data list two other predictions, both with no supporting trials: primary hereditary glaucoma (0.9940, L5) and open-angle glaucoma (0.9936). The open-angle glaucoma entry has only indirect observational and exploratory literature, mainly nutrient-status associations. It does not establish treatment benefit and is not analysed further here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
All nine licences below are valid records. No approved indication text or dosage form is recorded for any of them.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02193221 | THIAMIJECT INJECTION - LIQ IM IV 100MG/ML | Not recorded | Not recorded |
| 00816078 | VITAMIN B1 | Not recorded | Not recorded |
| 00586315 | MULTI 1000 | Not recorded | Not recorded |
| 02100606 | MULTI 12 | Not recorded | Not recorded |
| 02242529 | MULTI-12/K1 PEDIATRIC | Not recorded | Not recorded |
The remaining four licences (PREGVIT FOLIC 5, PREGNANCY MULTIVITAMIN, PREGVIT, PREGNANCY MULTIVITAMIN FOLIC 5) are also valid and have no recorded indication text.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone. No clinical trials or publications address this disease, and no plausible mechanistic link to thyroid hormone receptor beta is evident.
To proceed, the following is needed:
- Health Canada package insert warnings, contraindications and approved indication text (currently missing, and blocking safety screening)
- Mechanism of action data for thiamine
- Any preclinical or clinical evidence that directly studies thiamine in this disease
- A mechanistic rationale linking thiamine to thyroid hormone receptor beta signalling
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.